Seeking Alpha

Dendreon (DNDN +1.2%) preliminary adjusted FQ4 net product revenues +5% Q/Q to $81.6M vs...

Dendreon (DNDN +1.2%) preliminary adjusted FQ4 net product revenues +5% Q/Q to $81.6M vs consensus of $83.66M. Community sales hit record, with urology +25%, oncology +4%. Community accounts represent 71% of total sales, up from 58% in Q4 2011. Dendreon benefits from the increased use of its Provenge prostate cancer drug in community oncology and urology settings. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|